Traders Purchase High Volume of Call Options on Neumora Therapeutics (NASDAQ:NMRA)

Neumora Therapeutics, Inc. (NASDAQ:NMRA) was the recipient of some unusual options trading on Monday. Stock traders acquired 5,936 call options on the stock. This is an increase of approximately 45% compared to the average volume of 4,096 call options.

Insider Buying and Selling at Neumora Therapeutics

In other news, insider Robert A. Lenz sold 5,563 shares of the business’s stock in a transaction dated Wednesday, October 9th. The stock was sold at an average price of $15.01, for a total value of $83,500.63. Following the sale, the insider now directly owns 322,966 shares in the company, valued at $4,847,719.66. The trade was a 1.69 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Matthew K. Fust sold 14,049 shares of the firm’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $17.03, for a total transaction of $239,254.47. Following the transaction, the director now directly owns 20,100 shares of the company’s stock, valued at $342,303. This represents a 41.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 26.40% of the company’s stock.

Institutional Investors Weigh In On Neumora Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC boosted its holdings in shares of Neumora Therapeutics by 54.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,979,847 shares of the company’s stock worth $26,159,000 after buying an additional 694,385 shares in the last quarter. State Street Corp boosted its stake in Neumora Therapeutics by 65.3% during the third quarter. State Street Corp now owns 1,790,707 shares of the company’s stock worth $23,655,000 after acquiring an additional 707,409 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Neumora Therapeutics by 139.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 698,255 shares of the company’s stock worth $9,224,000 after purchasing an additional 406,891 shares during the period. Callan Capital LLC increased its stake in Neumora Therapeutics by 222.6% in the second quarter. Callan Capital LLC now owns 661,194 shares of the company’s stock valued at $6,500,000 after purchasing an additional 456,207 shares in the last quarter. Finally, Auour Investments LLC bought a new stake in Neumora Therapeutics in the third quarter valued at $3,302,000. Institutional investors own 47.65% of the company’s stock.

Neumora Therapeutics Stock Up 14.3 %

Shares of NASDAQ:NMRA opened at $2.48 on Tuesday. The business has a fifty day simple moving average of $10.28 and a 200 day simple moving average of $11.46. Neumora Therapeutics has a 12-month low of $1.83 and a 12-month high of $21.00. The firm has a market cap of $400.67 million, a P/E ratio of -1.33 and a beta of 2.71.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). During the same period in the prior year, the business earned ($1.14) earnings per share. As a group, equities research analysts expect that Neumora Therapeutics will post -1.61 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on NMRA shares. Royal Bank of Canada lowered Neumora Therapeutics from an “outperform” rating to a “sector perform” rating and dropped their price objective for the company from $29.00 to $4.00 in a research note on Thursday, January 2nd. Needham & Company LLC restated a “buy” rating and issued a $23.00 price target on shares of Neumora Therapeutics in a research note on Thursday, January 2nd. Bank of America decreased their price objective on Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating on the stock in a report on Monday. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Neumora Therapeutics in a research report on Friday. Finally, JPMorgan Chase & Co. lowered Neumora Therapeutics from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $18.00 to $15.00 in a report on Tuesday, November 5th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.50.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.